ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Zymeworks, CSPC Pharmaceutical Group and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Zymeworks×CSPC Pharmaceutical Group×AstraZeneca×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ZymeworksCSPC Pharmaceutical GroupAstraZeneca
studies on the registry513554,197
open to participants now1170298
phase 3 studies under way164200
reach primary completion within a year255168
programswith a study of their own in two years168+3 named only119+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseZymeworksCSPC Pharmaceutical GroupAstraZeneca
Phase 1

Zymeworks: 1 of its 1 programs at phase 1

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1
100%

CSPC Pharmaceutical Group: 16 of its 68 programs at phase 1

  1. JMT206phase 1
  2. SYH2082phase 1
  3. JMT106phase 1
  4. paclitaxel cationic liposome for injectionphase 1
  5. palbociclibphase 1

and 11 more — sign in to see them all

24%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 200%

CSPC Pharmaceutical Group: 26 of its 68 programs at phase 2

  1. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  2. SYS6006 COVID-19 vaccinephase 2
  3. ATM Inhibitor SYH2051phase 2
  4. SYH2069phase 2
  5. SYH2070phase 2

and 21 more — sign in to see them all

38%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
Phase 300%

CSPC Pharmaceutical Group: 25 of its 68 programs at phase 3

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. anbenitamabphase 3

and 20 more — sign in to see them all

37%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies00%

CSPC Pharmaceutical Group: 1 of its 68 programs at approved, new studies

  1. Tenecteplaseapproved, new study
1%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Zymeworks1 readouts · 0 phase 3··········

Zymeworks, Sep ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1 · Sep 0 · NCT07164313
·
CSPC Pharmaceutical Group39 readouts · 6 phase 3

CSPC Pharmaceutical Group, Nov ’26: 3 programs whose next study reaches primary completion

  1. SYH2061phase 1 · Nov 24 · NCT07241910
  2. Anti-EGFR Antibody-drug Conjugate CPO301phase 3 · Nov 30 · NCT07256509
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2 · Nov 30 · NCT07280832

CSPC Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. anbenitamabphase 3 · Dec 16 · NCT06747338
  2. Docetaxelphase 3 · Dec 16 · NCT06747338
  3. glumetinibphase 3 · Dec 25 · NCT06525350
  4. paliperidoneno phase · Dec 31 · NCT07493551
  5. SYH2059phase 2 · Dec 31 · NCT07510958

and 1 more — sign in to see them all

CSPC Pharmaceutical Group, Jan ’27: 4 programs whose next study reaches primary completion

  1. SYH2056phase 1 · Jan 30 · NCT07771777
  2. SYH2082phase 1 · Jan 30 · NCT07532655
  3. SYS6005phase 1 · Jan 30 · NCT06958679
  4. SYH2062phase 2 · Jan 31 · NCT07940075

CSPC Pharmaceutical Group, Feb ’27: 4 programs whose next study reaches primary completion

  1. SYH2072phase 2 · Feb 1 · NCT07647783
  2. SYH2092phase 1 · Feb 9 · NCT07776041
  3. JMT206phase 1 · Feb 28 · NCT07840729
  4. SYS6040phase 1 · Feb 28 · NCT06970795

CSPC Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. A zoster mRNA vaccine SYS6017phase 2 · Mar 10 · NCT07354659
  2. becotatugphase 3 · Mar 26 · NCT06380348
  3. SYS6041phase 2 · Mar 28 · NCT07744763

CSPC Pharmaceutical Group, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. enlonstobartphase 3 · Apr 0 · NCT06136988
  2. CPO-107phase 2 · Apr 1 · NCT07029139
  3. SYHX1901phase 3 · Apr 28 · NCT06943950
  4. SYH2070phase 2 · Apr 30 · NCT07695597
  5. SYH2085phase 2 · Apr 30 · NCT07798193

CSPC Pharmaceutical Group, May ’27: 1 program whose next study reaches primary completion

  1. anbenitamab repodatecanphase 3 · May 29 · NCT07545044

CSPC Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. ATM Inhibitor SYH2051phase 2 · Jun 15 · NCT06775236
  2. bempedoic acidphase 3 · Jun 30 · NCT07623915

CSPC Pharmaceutical Group, Jul ’27: 4 programs whose next study reaches primary completion

  1. ocankitugphase 3 · Jul 1 · NCT07418736
  2. SYH2053phase 3 · Jul 15 · NCT07938034
  3. SYS6045phase 2 · Jul 30 · NCT07122063
  4. CHO cellphase 2 · Jul 31 · NCT07892989

CSPC Pharmaceutical Group, Aug ’27: 2 programs whose next study reaches primary completion

  1. SYHX2008phase 3 · Aug 1 · NCT06505395
  2. JMT203phase 2 · Aug 14 · NCT06868849

CSPC Pharmaceutical Group, Sep ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Aripiprazoleno phase · Sep 5 · NCT07547384
  2. SYH2069phase 2 · Sep 28 · NCT07796477
  3. Tenecteplaseapproved, new study · Sep 30 · NCT07201688

CSPC Pharmaceutical Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. palbociclibphase 1 · Oct 0 · NCT06941142
  2. Sirolimusphase 3 · Oct 0 · NCT06941142
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Zymeworks

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

CSPC Pharmaceutical Group

New programs 6

  • SYH9061phase 2 · first study · Nov 2 · Idiopathic Pulmonary Fibrosis
  • SYS6062phase 2 · first study · Oct 20 · Stomach Neoplasms
  • CHO cellphase 2 · first study · Oct 19 · COVID-19
  • SYH2066phase 2 · first study · Oct 11 · Respiratory Syncytial Virus Infections
  • Generic Drugphase 3 · first study · Sep 28 · Triple Negative Breast Neoplasms
  • SYS6088phase 2 · first study · Sep 20 · Neoplasms

Reached a new phase 3

  • SYH2072phase 2 · Oct 28 · Hyperaldosteronism
  • SYH2069phase 2 · Aug 25 · Obesity
  • SYH2085phase 2 · Aug 25 · Influenza, Human

Study stopped 0

None

Primary completion later 2

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 42 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionZymeworksCSPC Pharmaceutical GroupAstraZeneca
Carcinoma, Hepatocellularall three · compare here

Zymeworks in Carcinoma, Hepatocellular: 1 program

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1

Their studies: Zymeworks’ studies of Carcinoma, Hepatocellular in search

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

CSPC Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. glumetinibphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Breast Neoplasms: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. anbenitamabphase 3
  4. Sirolimusphase 3
  5. anbenitamab repodatecanphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 9 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 4 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Stomach Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Stomach Neoplasms: 7 programs

  1. Docetaxelphase 3
  2. enlonstobartphase 3
  3. anbenitamabphase 3
  4. anbenitamab repodatecanphase 3
  5. trastuzumab envedotinphase 3

and 2 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Stomach Neoplasms in search

Prostatic Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Prostatic Neoplasms: 1 program

  1. Docetaxelphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Asthma2 of 3 · compare here–

CSPC Pharmaceutical Group in Asthma: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Asthma in search

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Renal Insufficiency2 of 3 · compare here–

CSPC Pharmaceutical Group in Renal Insufficiency: 3 programs

  1. Sirolimusphase 3
  2. SYH2053phase 3
  3. aprocitentanphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Renal Insufficiency in search

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Neoplasms2 of 3 · compare here–

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Obesity2 of 3 · compare here–

CSPC Pharmaceutical Group in Obesity: 5 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2
  3. SYH2082phase 1
  4. SYH2092phase 1
  5. SYH9017phase 1

Their studies: CSPC Pharmaceutical Group’s studies of Obesity in search

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

CSPC Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here–

CSPC Pharmaceutical Group in Squamous Cell Carcinoma of Head and Neck: 4 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. becotatugphase 3
  3. Sutantatug Envedotinphase 3
  4. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of Squamous Cell Carcinoma of Head and Neck in search

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 5 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. volrustomigphase 3
  4. monalizumabphase 3
  5. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Diabetes Mellitus, Type 22 of 3 · compare here–

CSPC Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Show all 42

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Zymeworks 1 of 1 · CSPC Pharmaceutical Group 25 of 68 · AstraZeneca 68 of 119 programs (45 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (CSPC Pharmaceutical Group: 3, AstraZeneca: 5).